Table 4.
Patient distribution in classes of standardized C-trough values around the mean value (0) for all anticoagulant drugs, with the number of patients and of thrombotic complications recorded in each class
| Classes of standardized C-trough values | Equivalent DOAC C-trough plasma levels (ng/mL) |
Patients, n | Follow-up, y | Thrombotic complication, n | Incidence, % pt/y (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apixaban |
Edoxaban |
Rivaroxaban |
Dabigatran |
||||||||
| 2.5 mg BID | 5 mg BID | 30 mg | 60 mg | 20 mg | 110 mg BID | 150 mg BID | |||||
| -1.00 or less | ≤41 | ≤61 | ≤8 | ≤7 | ≤6 | ≤46 | ≤37 | 89 | 83 | 4 | 4.82 (1.3-12.3) |
| From -0.99 to -0.50 | 44-77 | 63-94 | 9-23 | 8-24 | 8-22 | 51-78 | 38-68 | 442 | 430 | 7 | 1.63 (0.6-3.3) |
| From -0.49 to 0 | 78-113 | 95-128 | 24-39 | 25-42 | 23-37 | 81-109 | 69-99 | 525 | 513 | 6 | 1.17 (0.4-2.5) |
| From 0.01 to 0.50 | 114-146 | 129-160 | 40-54 | 43-58 | 38-52 | 115-138 | 101-128 | 279 | 277 | 3 | 1.08 (0.2-3.2) |
| From 0.51 to 1.00 | 149-179 | 163-195 | 55-70 | 60-73 | 53-67 | 143-163 | 132-163 | 129 | 119 | 1 | 0.84 (0.02-4.7) |
| >1.00 | 187-468 | 199-445 | 72-202 | 79-284 | 70-331 | 175-311 | 165-367 | 193 | 183 | 0 | 0 |
| --- | --- | --- | --- | --- | --- | --- | 1657 | 1605 | 21 | 1.31 (0.8-2.0) | |
The equivalent DOAC plasma levels at C-trough for each class are also reported.
BID, twice a day; CI, confidence interval.